Calypso Biotech SA

Calypso Biotech is an immunotherapy biotech company, spin-off from Merck Serono, that discovers and develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs. Calypso Biotech's portfolio consists of two preclinical therapeutic antibodies that intercept key immune checkpoints involved in multiple immune pathologies.